Odyssey Health Inc.
0.0770+0.00 (+4.05%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · ODYY · USD
Key Stats
Market Cap
7.45MP/E (TTM)
-Basic EPS (TTM)
-0.15Dividend Yield
0%Recent Filings
10-K
8-K
Odyssey secures BreastCheck rights
Odyssey Health, through subsidiary Odyssey Medical Devices, signed a master technology sub-license agreement on October 14, 2025, with NeuRX Health for exclusive worldwide rights to the FDA-registered BreastCheck®, a 15-minute at-home non-invasive test detecting breast abnormalities via temperature differences. The deal grants full access to intellectual property, know-how, and regulatory approvals for commercialization, with consideration tied to a percentage of equity line draws and future royalties per unit sold, pending closing conditions by October 30, 2025. This bolsters Odyssey's medtech portfolio amid rising breast cancer cases, yet hinges on funding and IP enforcement. Risks include third-party claims on the technology.
8-K
Odyssey Health raises $100K note
Odyssey Health secured $100,000 via a promissory note from accredited investor Peter D'Arruda, effective October 1, 2025, with 18% annual interest due in full by September 30, 2026. The deal includes a warrant for 100,000 common shares at $0.10 each, exercisable over five years. This infusion bolsters short-term liquidity. Yet dilution looms if warrants convert.
8-K
Odyssey issues convertible note
Odyssey Health secured $173,000 in net proceeds by issuing Mast Hill Fund a $220,000 one-year promissory note at 10% interest, convertible at 85% of the prior ten-day VWAP, plus a five-year warrant for 1,000,000 shares at $0.10 each with cashless exercise option. This financing bolsters working capital amid Odyssey's OTC trading status, yet the discounted conversion risks heavy dilution for existing shareholders. Deal closed August 27, 2025.
8-K
Note maturity extended
Odyssey Health, Inc. extended the maturity of its $300,000 promissory note with accredited investor Peter J. D'Arruda from the original date to January 31, 2026, effective August 14, 2025. This amendment preserves all other terms of the August 14, 2024 note. The move buys the company breathing room on its debt obligations. No further financial impacts were disclosed.
IPO
Employees
Sector
Industry
ADGM
Adagio Medical Holdings, Inc
1.19-0.08
BWAY
Brainsway Ltd.
16.80+0.22
CBLL
CeriBell, Inc.
12.03-0.80
COCH
Envoy Medical, Inc.
0.78-0.02
HSCS
HeartSciences Inc.
2.97-0.19
HSDT
Solana Company
6.78+0.17
IINN
Inspira Technologies Oxy B.H.N.
1.00-0.05
INSP
Inspire Medical Systems, Inc.
75.17-2.00
PMI
Picard Medical, Inc.
3.28-0.77
VYCO
Vycor Medical, Inc.
0.15+0.00